🚀 From Google Podcasts to Moon FM in No Time: Your Hassle-Free Migration Guide
👉

NEJM Interviews

NEJM Group

Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.

  • 8 minutes 47 seconds
    NEJM Interview: Jonathan Oberlander on the implications of the 2024 U.S. elections for health care reform.
    Jonathan Oberlander is a professor of social medicine and of health policy and management at the University of North Carolina at Chapel Hill. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Oberlander. Health Care Reform and the 2024 U.S. Elections — Low Visibility, High Stakes. N Engl J Med 2024;391:1169-1171.
    2 October 2024, 3:01 pm
  • 10 minutes 12 seconds
    NEJM Interview: Abigail Cutler on providing training in abortion care to Ob/Gyn residents amid legal restrictions.
    Abigail Cutler is an assistant professor and associate residency program director in the Department of Obstetrics and Gynecology at the University of Wisconsin School of Medicine and Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.S. Cutler and E. Hartenbach. Dobbs Revisited — Addressing Effects on Resident Training in Obstetrics and Gynecology. N Engl J Med 2024;391:1073-1075.
    25 September 2024, 3:01 pm
  • 11 minutes 56 seconds
    NEJM Interview: Charles Weijer on the potential benefits and ethical challenges associated with pragmatic and cluster RCTs.
    Charles Weijer is a professor in the Departments of Medicine and Philosophy at Western University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. C. Weijer and M. Taljaard. Ethical Challenges Associated with Pragmatic and Cluster RCTs. N Engl J Med 2024;391:969-971.
    18 September 2024, 3:01 pm
  • 2 minutes 56 seconds
    NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    15 September 2024, 3:01 pm
  • 2 minutes 58 seconds
    NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    15 September 2024, 3:01 pm
  • 3 minutes 11 seconds
    NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    14 September 2024, 3:01 pm
  • 3 minutes 44 seconds
    NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    14 September 2024, 3:01 pm
  • 3 minutes 41 seconds
    NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    14 September 2024, 3:01 pm
  • 3 minutes 25 seconds
    NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    14 September 2024, 3:01 pm
  • 3 minutes 23 seconds
    NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    14 September 2024, 3:01 pm
  • 2 minutes 50 seconds
    NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
    Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
    13 September 2024, 3:01 pm
  • More Episodes? Get the App
About NEJM Interviews
Links
Listeners Also Subscribed To
© MoonFM 2024. All rights reserved.